{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:01:22Z","timestamp":1791669682721,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Peritoneal spread indicates poor prognosis in patients with serous ovarian carcinoma (SOC) and is generally treated by surgical cytoreduction and chemotherapy. Novel treatment options are urgently needed to improve patient outcome. Clinically relevant cell lines and patient-derived xenograft (PDX) models are of critical importance to therapeutic regimen evaluation. Here, a PDX model was established, by orthotopic engraftment after subperitoneal tumor slurry injection of low-grade SOC, resulting in an early-stage transplantable peritoneal metastasis (PM)-PDX model. Histology confirmed the micropapillary and cribriform growth pattern with intraluminal tumor budding and positivity for PAX8 and WT1. PM-PDX dissociated cells show an epithelial morphotype with a 42\u2009h doubling time and 40% colony forming efficiency, they are low sensitive to platinum derivatives and highly sensitive to paclitaxel (IC50: 6.3\u2009\u00b1\u20092.2\u2009nM, mean \u00b1 SEM). The patient primary tumor, PM, PM-PDX and derived cell line all show a\n                    <jats:italic>KRAS<\/jats:italic>\n                    c.35\u2009G\u2009&gt;\u2009T (p.(Gly12Val)) mutation and show sensitivity to the MEK inhibitor trametinib\n                    <jats:italic>in vitro<\/jats:italic>\n                    (IC50: 7.2\u2009\u00b1\u20090.5\u2009nM, mean \u00b1 SEM) and in the PM mouse model. These preclinical models closely reflecting patient tumors are useful to further elucidate LGSOC disease progression, therapy response and resistance mechanisms.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-63738-6","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T06:04:37Z","timestamp":1587449077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Elien","family":"De Thaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van de Vijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joni","family":"Van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Taminau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Wagemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Van Dorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Berx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Van Bocxlaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"De Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"63738_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians 68, 394, https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"63738_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/cancers10110433","volume":"10","author":"J Kim","year":"2018","unstructured":"Kim, J. et al. Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel) 10, 433, https:\/\/doi.org\/10.3390\/cancers10110433 (2018).","journal-title":"Cancers (Basel)"},{"key":"63738_CR3","first-page":"161","volume":"27","author":"RA Soslow","year":"2008","unstructured":"Soslow, R. A. Histologic Subtypes of Ovarian Carcinoma. International Journal of Gynecological Pathology 27, 161 (2008).","journal-title":"International Journal of Gynecological Pathology"},{"key":"63738_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","volume":"16","author":"R Vang","year":"2009","unstructured":"Vang, R., Shih, I.-M. & Kurman, R. J. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16, 267, https:\/\/doi.org\/10.1097\/PAP.0b013e3181b4fffa (2009).","journal-title":"Adv Anat Pathol"},{"key":"63738_CR5","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. The Lancet 384, 1376, https:\/\/doi.org\/10.1016\/S0140-6736(13)62146-7 (2014).","journal-title":"The Lancet"},{"key":"63738_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1369\/0022155417742897","volume":"66","author":"J van Baal","year":"2018","unstructured":"van Baal, J. et al. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. Journal of Histochemistry & Cytochemistry 66, 18, https:\/\/doi.org\/10.1369\/0022155417742897 (2018).","journal-title":"Journal of Histochemistry & Cytochemistry"},{"key":"63738_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.clinthera.2018.01.012","volume":"40","author":"MH Vetter","year":"2018","unstructured":"Vetter, M. H. & Hays, J. L. Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions. Clinical Therapeutics 40, 361, https:\/\/doi.org\/10.1016\/j.clinthera.2018.01.012 (2018).","journal-title":"Clinical Therapeutics"},{"key":"63738_CR8","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/ijgc-2019-IGCS.1","volume":"29","author":"R Grisham","year":"2019","unstructured":"Grisham, R. et al. 1 MILO\/ENGOT-OV11: Phase-3 study of binimetinib versus physician\u2019s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. International Journal of Gynecologic Cancer 29, A1, https:\/\/doi.org\/10.1136\/ijgc-2019-IGCS.1 (2019).","journal-title":"International Journal of Gynecologic Cancer"},{"key":"63738_CR9","doi-asserted-by":"publisher","unstructured":"Gershenson, D. M. et al. A randomized phase II\/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer. Annals of Oncology 30, https:\/\/doi.org\/10.1093\/annonc\/mdz394.058 (2019).","DOI":"10.1093\/annonc\/mdz394.058"},{"key":"63738_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbcan.2018.06.004","volume":"1870","author":"M Ibarrola-Villava","year":"2018","unstructured":"Ibarrola-Villava, M., Cervantes, A. & Bardelli, A. Preclinical models for precision oncology. Biochimica Et Biophysica Acta-Reviews on Cancer 1870, 239, https:\/\/doi.org\/10.1016\/j.bbcan.2018.06.004 (2018).","journal-title":"Biochimica Et Biophysica Acta-Reviews on Cancer"},{"key":"63738_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/2395-3977.196913","volume":"2","author":"M Perez","year":"2016","unstructured":"Perez, M., Navas, L. & Carnero, A. Patient-derived xenografts as models for personalized medicine research in cancer. Cancer Translational Medicine 2, 197, https:\/\/doi.org\/10.4103\/2395-3977.196913 (2016).","journal-title":"Cancer Translational Medicine"},{"key":"63738_CR12","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper, O. et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nature Medicine 25, 838, https:\/\/doi.org\/10.1038\/s41591-019-0422-6 (2019).","journal-title":"Nature Medicine"},{"key":"63738_CR13","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1158\/0008-5472.can-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas, D. & Hannon, G. J. Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models. Cancer Research 73, 5315, https:\/\/doi.org\/10.1158\/0008-5472.can-13-1069 (2013).","journal-title":"Cancer Research"},{"key":"63738_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2017.307","volume":"50","author":"J Jung","year":"2018","unstructured":"Jung, J., Seol, H. S. & Chang, S. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research. Cancer Research and Treatment 50, 1, https:\/\/doi.org\/10.4143\/crt.2017.307 (2018).","journal-title":"Cancer Research and Treatment"},{"key":"63738_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2353\/ajpath.2007.060929","volume":"170","author":"JE Talmadge","year":"2007","unstructured":"Talmadge, J. E., Singh, R. K., Fidler, I. J. & Raz, A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. American Journal of Pathology 170, 793, https:\/\/doi.org\/10.2353\/ajpath.2007.060929 (2007).","journal-title":"American Journal of Pathology"},{"key":"63738_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day, C. P., Merlino, G. & Van Dyke, T. Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges. Cell 163, 39, https:\/\/doi.org\/10.1016\/j.cell.2015.08.068 (2015).","journal-title":"Cell"},{"key":"63738_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat, J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Archiv 460, 237, https:\/\/doi.org\/10.1007\/s00428-012-1203-5 (2012).","journal-title":"Virchows Archiv"},{"key":"63738_CR18","first-page":"14","volume":"4","author":"N Hasan","year":"2015","unstructured":"Hasan, N., Ohman, A. W. & Dinulescu, D. M. The promise and challenge of ovarian cancer models. Translational Cancer Research 4, 14 (2015).","journal-title":"Translational Cancer Research"},{"key":"63738_CR19","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nature Medicine 21, 1318, https:\/\/doi.org\/10.1038\/nm.3954 (2015).","journal-title":"Nature Medicine"},{"key":"63738_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3716-4","volume":"17","author":"RF da Silva","year":"2017","unstructured":"da Silva, R. F. et al. CAISMOV24, a new human low-grade serous ovarian carcinoma cell line. BMC Cancer 17, 756, https:\/\/doi.org\/10.1186\/s12885-017-3716-4 (2017).","journal-title":"BMC Cancer"},{"key":"63738_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0725-1","volume":"19","author":"ML Fernandez","year":"2019","unstructured":"Fernandez, M. L. et al. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. Cancer Cell Int 19, 10, https:\/\/doi.org\/10.1186\/s12935-019-0725-1 (2019).","journal-title":"Cancer Cell Int"},{"key":"63738_CR22","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1093\/annonc\/mdw089","volume":"27","author":"A Malpica","year":"2016","unstructured":"Malpica, A. & Wong, K.-K. The molecular pathology of ovarian serous borderline tumors\u2020. Annals of Oncology 27, i16, https:\/\/doi.org\/10.1093\/annonc\/mdw089 (2016).","journal-title":"Annals of Oncology"},{"key":"63738_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s004280050314","volume":"434","author":"C Haas","year":"1999","unstructured":"Haas, C., Diebold, J., Hirschmann, A., Rohrbach, H. & L\u00f6hrs, U. In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential. Virchows Archiv 434, 117 (1999).","journal-title":"Virchows Archiv"},{"key":"63738_CR24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","volume":"95","author":"G Singer","year":"2003","unstructured":"Singer, G. et al. Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. JNCI: Journal of the National Cancer Institute 95, 484, https:\/\/doi.org\/10.1093\/jnci\/95.6.484 (2003).","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"63738_CR25","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","volume":"177","author":"K-K Wong","year":"2010","unstructured":"Wong, K.-K. et al. BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas. The American Journal of Pathology 177, 1611, https:\/\/doi.org\/10.2353\/ajpath.2010.100212 (2010).","journal-title":"The American Journal of Pathology"},{"key":"63738_CR26","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s12253-010-9345-8","volume":"17","author":"I Vereczkey","year":"2011","unstructured":"Vereczkey, I. et al. Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors. Pathology & Oncology Research 17, 551, https:\/\/doi.org\/10.1007\/s12253-010-9345-8 (2011).","journal-title":"Pathology & Oncology Research"},{"key":"63738_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1746-1596-8-21","volume":"8","author":"D Sundov","year":"2013","unstructured":"Sundov, D. et al. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS\/BRAF mutation in ovarian serous carcinomas. Diagn Pathol 8, 21, https:\/\/doi.org\/10.1186\/1746-1596-8-21 (2013).","journal-title":"Diagn Pathol"},{"key":"63738_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2014.01.008","volume":"133","author":"CR Miller","year":"2014","unstructured":"Miller, C. R., Oliver, K. E. & Farley, J. H. MEK1\/2 inhibitors in the treatment of gynecologic malignancies. Gynecologic Oncology 133, 128, https:\/\/doi.org\/10.1016\/j.ygyno.2014.01.008 (2014).","journal-title":"Gynecologic Oncology"},{"key":"63738_CR29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","volume":"17","author":"AG Gilmartin","year":"2011","unstructured":"Gilmartin, A. G. et al. GSK1120212 (JTP-74057) is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition. Clinical Cancer Research 17, 989, https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2200 (2011).","journal-title":"Clinical Cancer Research"},{"key":"63738_CR30","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.18632\/oncotarget.747","volume":"3","author":"T Yoshida","year":"2012","unstructured":"Yoshida, T. et al. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1\/2. Oncotarget 3, 1533, https:\/\/doi.org\/10.18632\/oncotarget.747 (2012).","journal-title":"Oncotarget"},{"key":"63738_CR31","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","volume":"13","author":"TC Yeh","year":"2007","unstructured":"Yeh, T. C. et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1\/2 Inhibitor. Clinical Cancer Research 13, 1576, https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1150 (2007).","journal-title":"Clinical Cancer Research"},{"key":"63738_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jbiotec.2015.01.012","volume":"205","author":"C Mas","year":"2015","unstructured":"Mas, C. et al. Antitumour efficacy of the selumetinib and trametinib MEK inhibitors in a combined human airway\u2013tumour\u2013stroma lung cancer model. Journal of Biotechnology 205, 111, https:\/\/doi.org\/10.1016\/j.jbiotec.2015.01.012 (2015).","journal-title":"Journal of Biotechnology"},{"key":"63738_CR33","first-page":"23","volume":"39","author":"T Yamaguchi","year":"2011","unstructured":"Yamaguchi, T., Kakefuda, R., Tajima, N., Sowa, Y. & Sakai, T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1\/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. International Journal of Oncology 39, 23 (2011).","journal-title":"International Journal of Oncology"},{"key":"63738_CR34","first-page":"2235","volume":"6","author":"ML Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez, M. L. et al. Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. Am J Cancer Res 6, 2235 (2016).","journal-title":"Am J Cancer Res"},{"key":"63738_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/humu.22739","volume":"36","author":"K De Leeneer","year":"2015","unstructured":"De Leeneer, K. et al. Flexible, Scalable, and Efficient Targeted Resequencing on a Benchtop Sequencer for Variant Detection in Clinical Practice. Human Mutation 36, 379, https:\/\/doi.org\/10.1002\/humu.22739 (2015).","journal-title":"Human Mutation"},{"key":"63738_CR36","unstructured":"RStudio: Integrated Development for R (Boston, MA, 2016)."},{"key":"63738_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nature Biotechnology 29, 24\u201326, https:\/\/doi.org\/10.1038\/nbt.1754 (2011).","journal-title":"Nature Biotechnology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63738-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T04:40:21Z","timestamp":1670301621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63738"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63738-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/784959","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"4 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6688"}}